Drug intelligence / Profile preview

cefotaxime + mezlocillin

Development stage: Preclinical
Lead developer: Roche
Modality: Small Molecules
Administration: Intramuscular, Intravenous

Overview

Combination of cefotaxime, a third-generation cephalosporin antibiotic, and mezlocillin, a penicillin beta-lactam antibiotic. This combination has been studied for treating serious bacterial infections. Pharmacokinetic studies show that mezlocillin decreases the total body clearance of cefotaxime by 42%, potentially enhancing cefotaxime's effectiveness. The combination provides broad-spectrum coverage against both gram-positive and gram-negative bacteria.

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefotaxime + mezlocillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefotaxime + mezlocillin.

Explore the full profile